The human 26S proteasome is a target of antiretroviral agents

AIDS

Volumn 16, Issue 5, 2002, Pages 693-700

  Piccinini, Marco ^a   Rinaudo, Maria T ^a,b   Chiapello, Nadia ^a   Ricotti, Emanuela ^a   Baldovino, Simone ^a   Mostert, Michael ^a   Tovo, Pier Angelo ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b Sezione di Biochimica   (Italy)

Author keywords

Antiretroviral agents; I B ; NF B; Proteasome; Ubiquitin protein conjugates

Indexed keywords

ANTIRETROVIRUS AGENT; CHYMOTRYPSIN; INDINAVIR; LAMIVUDINE; PROTEASOME; VIRUS ENZYME; ZIDOVUDINE;

ARTICLE; CATALYSIS; CLINICAL IMMUNOLOGY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HYDROLYSIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PURIFICATION; VIRUS REPLICATION;

ANTI-HIV AGENTS; DNA-BINDING PROTEINS; DRUG DELIVERY SYSTEMS; HIV PROTEASE INHIBITORS; HUMANS; I-KAPPA B PROTEINS; INDINAVIR; JURKAT CELLS; LAMIVUDINE; NF-KAPPA B; PEPTIDE HYDROLASES; PROTEASOME ENDOPEPTIDASE COMPLEX; REVERSE TRANSCRIPTASE INHIBITORS; UBIQUITIN; ZIDOVUDINE;

EID: 0037192550     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200203290-00004     Document Type: Article

References (43)

1. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study. Swiss HIV Cohort study
2. HIV treatment failure: Testing for HIV resistance in clinical practice
3. Dissociation of immunologic and virologic responses to highly active antiretroviral therapy
4. Inhibition of immune function by antiviral drugs
5. The HIV protease inhibitor indinavir inhibits cell-cycle progression in vitro in lymphocytes of HIV-infected and uninfected individuals
6. Highly active antiretroviral therapy inhibits cytokine production in HIV uninfected subjects
7. An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses
8. The proteasome: Paradigm of a self-compartmentalizing protease
9. The proteasome
10. Identification of the yeast 20S proteasome catalytic centers and subunit interactions required for active-site formation
11. The base of the proteasome regulatory particle exhibits chaperone-like activity
12. Regulatory subunit interactions of the 26S proteasome, a complex problem
13. Structural and functional characterization of 20S and 26S proteasomes from bovine brain
14. The proteasome activator 11S reg (PA28) and class I antigen presentation
15. Multiple forms of the 20S multicatalytic and the 26S ubiquitin/ATP-dependent proteases from rabbit reticulocyte lysate
16. The ubiquitin-proteasome pathway: On protein death and cell life
17. The NF-κB and IκB proteins: New discoveries and insights
18. The ubiquitin-proteasome pathway and pathogenesis of human diseases
19. Phosphorylation meets ubiquitination: The control of NF-[kappa]B activity
20. Proteasome inhibition interferes with Gag polyprotein processing, release, and maturation of HIV-1 and HIV-2
21. The ubiquitin-proteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB
22. Proteasomes are a target of the antitumor drug vinblastine
23. Silver staining of 2-D electrophoresis gels
24. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications
25. Affinity purification and characterization of protein gene product 9.5 (PGP 9.5) from retina
26. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
27. Inhibition of the proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin
28. Control of I kappa B-alpha proteolysis by site-specific, signal-induced phosphorylation
29. The antitumor drug aclacinomycin A, which inhibits the degradation of ubiquitinated proteins, shows selectivity for the chymotrypsin-like activity of the bovine pituitary 20S proteasome
30. The bioequivalence of a fixed dose triple NRTI combination tablet containing abacavir, lamivudine, and zidovudine
31. Single-dose pharmacokinetics and safety of abacavir (1592U89), zidovudine, and lamivudine administered alone and in combination in adults with human immunodeficiency virus infection
32. A cDNA for a protein that interacts with the human immunodeficiency virus Tat transactivator
33. An inducible transcription factor activates expression of human immunodeficiency virus in T cells
34. Activation of HIV transcription by Tat
35. Permanent occupancy of the immunodeficiency virus type 1 enhancer by NF-κB is needed for persistent viral replication in monocytes
36. The in vitro induction of human immunodeficiency virus (HIV) replication in purified protein derivate-positive HIV-infected persons by recall antigen response to Mycobacterium tuberculosis is the result of a balance of the effects of endogenous interleukine-2 and pro-inflammatory and anti-inflammatory cytokines
37. Protein degradation and apoptotic death in lymphocytes during FIV infection: Activation of the ubiquitin-proteasome proteolytic system
38. Proteasome regulation of Fas ligand cytotoxicity
39. Spontaneous and anti-Fas-induced apoptosis in lymphocytes from HIV-infected patients undergoing highly active anti-retroviral therapy
40. Ubiquitin and proteasome gene expression is increased in skeletal muscle of slim AIDS patients
41. HIV-1 tat molecular diversity and induction of TNF-alpha: Implications for HIV-induced neurological disease
42. Transient exposure to HIV-1 Tat protein results in cytokine production in macrophages and astrocytes
43. Proteasome blockers inhibit TNF-α release by lipopolysaccharide stimulated macrophages and microglia: Implications for HIV-1 dementia